

Christoph Henkenberens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2740360/publications.pdf>

Version: 2024-02-01

41
papers

1,065
citations

361413

20
h-index

434195

31
g-index

42
all docs

42
docs citations

42
times ranked

1682
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Volumetric ⁶⁸ Ga-DOTA-TATE PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with metastatic gastroenteropancreatic neuroendocrine tumors. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2022, 66, . | 0.7 | 14 |
| 2 | Intraprostatic Tumor Segmentation on PSMA PET Images in Patients with Primary Prostate Cancer with a Convolutional Neural Network. Journal of Nuclear Medicine, 2021, 62, 823-828. | 5.0 | 32 |
| 3 | Prostate-specific Membrane Antigen Positron Emission Tomography“ detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation. European Urology Focus, 2021, 7, 309-316. | 3.1 | 34 |
| 4 | Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer“ results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group. Strahlentherapie Und Onkologie, 2021, 197, 385-395. | 2.0 | 9 |
| 5 | Predictive and Prognostic Impact of Blood-Based Inflammatory Biomarkers in Patients with Gastroenteropancreatic Neuroendocrine Tumors Commencing Peptide Receptor Radionuclide Therapy. Diagnostics, 2021, 11, 504. | 2.6 | 12 |
| 6 | Assessment of ¹³ H2AX and 53BP1 Foci in Peripheral Blood Lymphocytes to Predict Subclinical Hematotoxicity and Response in Somatostatin Receptor-Targeted Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors. Cancers, 2021, 13, 1516. | 3.7 | 5 |
| 7 | Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer. Frontiers in Oncology, 2021, 11, 664225. | 2.8 | 7 |
| 8 | Value of PET imaging for radiation therapy. Nuklearmedizin - NuclearMedicine, 2021, 60, 326-343. | 0.7 | 2 |
| 9 | Value of PET imaging for radiation therapy. Strahlentherapie Und Onkologie, 2021, 197, 1-23. | 2.0 | 16 |
| 10 | Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy. Strahlentherapie Und Onkologie, 2020, 196, 1006-1017. | 2.0 | 8 |
| 11 | Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [⁶⁸ Ga]PSMA-PET-guided metastasis-directed therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2328-2338. | 6.4 | 13 |
| 12 | Influence of short-term dexamethasone on the efficacy of ¹⁷⁷ Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Prostate, 2020, 80, 619-631. | 2.3 | 20 |
| 13 | Neuroendocrine Differentiation and Response to PSMA-Targeted Radioligand Therapy in Advanced Metastatic Castration-Resistant Prostate Cancer: A Single-Center Retrospective Study. Journal of Nuclear Medicine, 2020, 61, 1602-1606. | 5.0 | 25 |
| 14 | A novel open-source software-based high-precision workflow for target definition in cardiac radioablation. Journal of Cardiovascular Electrophysiology, 2020, 31, 2689-2695. | 1.7 | 28 |
| 15 | Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy“ a multicenter retrospective study. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1852-1863. | 6.4 | 16 |
| 16 | Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy. BMC Cancer, 2020, 20, 362. | 2.6 | 20 |
| 17 | Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference. Radiotherapy and Oncology, 2019, 141, 208-213. | 0.6 | 42 |
| 18 | Frequency and risk factors for arm lymphedema after multimodal breast-conserving treatment of nodal positive breast Cancer “ a long-term observation. Radiation Oncology, 2019, 14, 39. | 2.7 | 33 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Comparison of relative and absolute rectal doseâ€“volume parameters and clinical correlation with acute and late radiation proctitis in prostate cancer patients. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 103-112. | 2.0 | 7 |
| 20 | Patterns of Progression After 68Ga-PSMA-Ligand PET/CT-Guided Radiation Therapy for Recurrent Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 95-104. | 0.8 | 53 |
| 21 | Comparison of 68â€“Ga-PSMA ligand PET/CT versus conventional cross-sectional imaging for target volume delineation for metastasis-directed radiotherapy for metachronous lymph node metastases from prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 420-429. | 2.0 | 19 |
| 22 | PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 913-922. | 6.4 | 34 |
| 23 | Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stageâ€“III non-small cell lung cancer. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 79-90. | 2.0 | 30 |
| 24 | Patterns of relapse as determined by 68Ga-PSMA ligand PET/CT after radical prostatectomy. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 303-310. | 2.0 | 23 |
| 25 | Comorbidity indexing for prediction of the clinical outcome after stereotactic body radiation therapy in non-small cell lung cancer. <i>Radiation Oncology</i> , 2018, 13, 213. | 2.7 | 13 |
| 26 | Local recurrence of breast cancer: conventionally fractionated partial external beam re-irradiation with curative intention. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 806-814. | 2.0 | 28 |
| 27 | Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 960-968. | 6.4 | 70 |
| 28 | Multiple Time-Point 68Ga-PSMA I&T PET/CT for Characterization of Primary Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2017, 42, e286-e293. | 1.3 | 49 |
| 29 | Initial Experience with Volumetric 68Ga-PSMA I&T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1962-1968. | 5.0 | 120 |
| 30 | 68Ga-PSMA PET/CT Imaging Predicting Intraprostatic Tumor Extent, Extracapsular Extension and Seminal Vesicle Invasion Prior to Radical Prostatectomy in Patients with Prostate Cancer. <i>Nuclear Medicine and Molecular Imaging</i> , 2017, 51, 314-322. | 1.0 | 44 |
| 31 | Temporal and spatial dose distribution of radiation pneumonitis after concurrent radiochemotherapy in stage III non-small cell cancer patients. <i>Radiation Oncology</i> , 2017, 12, 165. | 2.7 | 5 |
| 32 | 68Ga-PSMA Ligand PET/CT-based Radiotherapy for Lymph Node Relapse of Prostate Cancer After Primary Therapy Delays Initiation of Systemic Therapy. <i>Anticancer Research</i> , 2017, 37, 1273-1280. | 1.1 | 25 |
| 33 | A new era of thoracic oncology? Ex-vivo stereotactic ablative radiosurgery within Ex-vivo Lung Treatment System as a hybrid therapy for unresectable locally advanced pulmonary malignancies. <i>Medical Hypotheses</i> , 2016, 92, 31-34. | 1.5 | 0 |
| 34 | Radiotherapy for isolated lymph node metastases in patients with locally advanced prostate cancer after primary therapy. <i>World Journal of Urology</i> , 2016, 34, 1239-1245. | 2.2 | 3 |
| 35 | 68Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 431-439. | 2.0 | 56 |
| 36 | 68Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging. <i>European Radiology</i> , 2016, 26, 4345-4353. | 4.5 | 73 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Inhalative steroids as an individual treatment in symptomatic lung cancer patients with radiation pneumonitis grade II after radiotherapy – a single-centre experience. <i>Radiation Oncology</i> , 2016, 11, 12. | 2.7 | 31 |
| 38 | Late radiation side effects, cosmetic outcomes and pain in breast cancer patients after breast-conserving surgery and three-dimensional conformal radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 8-16. | 2.0 | 33 |
| 39 | Clinical Value of Squamous Cell Carcinoma Antigen (SCCAg) in Anal Cancer - A Single-Center Retrospective Analysis. <i>Anticancer Research</i> , 2016, 36, 3173-7. | 1.1 | 3 |
| 40 | The Prognostic Value of Irradiated Lung Volumes on the Prediction of Intra-/ Post-Operative Mortality in Patients after Neoadjuvant Radiochemotherapy for Esophageal Cancer. A Retrospective Multicenter Study.. <i>Journal of Cancer</i> , 2015, 6, 254-260. | 2.5 | 2 |
| 41 | Reduced radiation dose for elective nodal irradiation in node-negative anal cancer: back to the roots?. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 845-854. | 2.0 | 7 |